MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/keae647

Медицинская библиотека · Rheumatology (Oxford, England) · 2025

Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study.

Anders Hans-Joachim, Chan Tak Mao, Sanchez-Guerrero Jorge, Wofsy David, Bensley Karen, Kim Lilianne, Lo Kim Hung, Shu Cathye, Shao Jie, Karyekar Chetan S, Diamond Betty

СтатьяРандомизированное исследованиеКлиническое исследование II фазыМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

Evaluate the efficacy and safety of guselkumab, an IL-23p19-subunit inhibitor, in a phase 2, multicentre, randomized, double-blind, placebo-controlled study of patients with active LN.

METHODS

Adults (18-75 years) with active LN [Class III-IV proliferative nephritis (kidney biopsy) and urine protein-to-creatinine ratio (UPCR) of ≥1 mg/mg despite standard-of-care therapy] were randomized (1:1; planned sample = 60) to receive i.v. infusions of guselkumab 400 mg or placebo at weeks 0, 4 and 8, then s.c. injections (guselkumab 200 mg or placebo) at week 12 and every 4 weeks through week 48 in addition to their background therapy. The primary endpoint was achievement of ≥50% decrease in proteinuria from baseline at week 24. Major secondary endpoints (week 24) were achievement of complete renal response (CRR), sustained reduction in steroid dose (≤10 mg/day prednisone/equivalent) from weeks 16-24, UPCR <0.5 mg/mg; <0.75 mg/mg, time to achieving CRR, and time to treatment failure. Safety was assessed through the end of the study.

RESULTS

Following enrolment challenges (COVID-19 pandemic; Ukraine/Russia crisis), the sponsor terminated the study early; 33 participants were randomized (placebo, n = 16; guselkumab, n = 17). At week 24, 56.3% (9/16) in the placebo group and 35.3% (6/17) in the guselkumab group achieved the primary endpoint. No apparent differences were observed in the secondary endpoints. Through end-of-study, 75% of placebo patients and 71% of guselkumab patients reported ≥1 adverse event; most were of mild-to-moderate severity.

CONCLUSION

Guselkumab+background therapy did not demonstrate superior reduction in proteinuria vs placebo+background therapy in this small cohort of patients with active LN. Safety results were consistent with the known safety profile of guselkumab.

TRIAL REGISTRATION: ClinicalTrials.gov: NCT04376827.

Для цитирования: Anders Hans-Joachim, Chan Tak Mao, Sanchez-Guerrero Jorge, Wofsy David, Bensley Karen, Kim Lilianne, Lo Kim Hung, Shu Cathye, Shao Jie, Karyekar Chetan S, Diamond Betty. Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study.. Rheumatology (Oxford, England). 2025. DOI: 10.1093/rheumatology/keae647.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.